Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments.
暂无分享,去创建一个
Robert Axelrod | Kenneth J Pienta | K. Pienta | R. Axelrod | D. Axelrod | Natalie Mcgregor | David E Axelrod | Natalie McGregor
[1] K. Pienta,et al. The "emigration, migration, and immigration"of prostate cancer. , 2005, Clinical prostate cancer.
[2] C. Guruvayoorappan. Tumor Versus Tumor-Associated Macrophages: How Hot is the Link? , 2008, Integrative cancer therapies.
[3] G. Clines,et al. Molecular mechanisms and treatment of bone metastasis , 2008, Expert Reviews in Molecular Medicine.
[4] Alissa M. Weaver,et al. Tumor Morphology and Phenotypic Evolution Driven by Selective Pressure from the Microenvironment , 2006, Cell.
[5] R. Weinberg,et al. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. , 2001, Experimental cell research.
[6] K. Pienta,et al. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites , 2008, Leukemia.
[7] A. Lipton. Treatment of bone metastases and bone pain with bisphosphonates. , 2007, Supportive cancer therapy.
[8] Monica L Guzman,et al. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. , 2008, Blood.
[9] B. Samuelsson,et al. Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. , 2008, Bone.
[10] Kornelia Polyak,et al. Microenvironmental regulation of cancer development. , 2008, Current opinion in genetics & development.
[11] A. Aboussekhra,et al. Breast carcinoma-associated fibroblasts and their counterparts display neoplastic-specific changes. , 2008, Cancer research.
[12] R. Kast,et al. Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: a report in a case of delayed graft failure. , 2009, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.
[13] L. Pelus. Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand , 2008, Current opinion in hematology.
[14] C. Hall,et al. Ecosystem Modeling in Theory and Practice: An Introduction with Case Histories , 1990 .
[15] A. Moustakas,et al. Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer , 2007 .
[16] M. Begon,et al. Ecology: Individuals, Populations and Communities , 1986 .
[17] S. Nadler,et al. CTLA4 Expression Is an Indicator and Regulator of Steady-State CD4+FoxP3+ T Cell Homeostasis1 , 2008, The Journal of Immunology.
[18] Matthew R. Smith. Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond. , 2008, Urologic oncology.
[19] L. Rosanò,et al. The endothelin axis in cancer. , 2008, The international journal of biochemistry & cell biology.
[20] J. McGee,et al. Macrophages in human breast disease: a quantitative immunohistochemical study. , 1988, British Journal of Cancer.
[21] Jeremy J. W. Chen,et al. Pathophysiology of tumor-associated macrophages. , 2008, Advances in clinical chemistry.
[22] G. Hahn,et al. Thermochemotherapy: synergism between hyperthermia (42-43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[23] R. L. Kitching. Systems Ecology: An Introduction to Ecological Modelling , 1983 .
[24] G. Tucker. Integrins: Molecular targets in cancer therapy , 2006, Current oncology reports.
[25] Yi Lu,et al. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. , 2006, Cancer research.
[26] A. Aranda-Anzaldo. Cancer Development and Progression: A Non-Adaptive Process Driven by Genetic Drift , 2001, Acta biotheoretica.
[27] Brian Bierie,et al. A delicate balance: TGF-beta and the tumor microenvironment. , 2007, Journal of cellular biochemistry.
[28] N. Nishimoto,et al. The blockade of IL-6 signaling in rational drug design. , 2008, Current pharmaceutical design.
[29] E. Small,et al. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. , 2006, Urologic oncology.
[30] S. Chiou,et al. cAMP/PKA Regulates Osteogenesis, Adipogenesis and Ratio of RANKL/OPG mRNA Expression in Mesenchymal Stem Cells by Suppressing Leptin , 2008, PloS one.
[31] E. Odum. Fundamentals of Ecology. , 1955 .
[32] P. Nowell. The clonal evolution of tumor cell populations. , 1976, Science.
[33] D. S. Coffey,et al. Hyperthermic biology and cancer therapies: a hypothesis for the "Lance Armstrong effect". , 2006, JAMA.
[34] Raghu Kalluri,et al. Fibroblasts in cancer , 2006, Nature Reviews Cancer.
[35] K. Pienta,et al. Annexin II/Annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer , 2008, Journal of cellular biochemistry.
[36] H. Kampinga,et al. Nuclear matrix as a target for hyperthermic killing of cancer cells. , 1998, Cell stress & chaperones.
[37] P. Allavena,et al. Cancer related inflammation: the macrophage connection. , 2008, Cancer letters.
[38] J. Wallace,et al. Suppressive effects of nitric oxide‐releasing prednisolone NCX‐1015 on the allergic pleural eosinophil recruitment in rats , 2008, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[39] A. Testori,et al. Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings. , 2008, Recent patents on anti-cancer drug discovery.
[40] Dennis C. Sgroi,et al. Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.
[41] A. J. Willis. The ecosystem : an evolving concept viewed historically , 1997 .
[42] J. Klein-Nulend,et al. Stem cells from adipose tissue allow challenging new concepts for regenerative medicine. , 2007, Tissue engineering.
[43] J. Gallagher. Advances in bone biology and new treatments for bone loss. , 2008, Maturitas.
[44] W. Hamilton,et al. The Evolution of Cooperation , 1984 .
[45] M. Kassem,et al. Demonstration of the presence of independent pre-osteoblastic and pre-adipocytic cell populations in bone marrow-derived mesenchymal stem cells. , 2008, Bone.
[46] H. Allgayer,et al. An introduction to molecular targeted therapy of cancer. , 2008, Advances in medical sciences.
[47] J. Masters,et al. Interferon-γ Reduces Cell Surface Expression of Annexin 2 and Suppresses the Invasive Capacity of Prostate Cancer Cells* , 2008, Journal of Biological Chemistry.
[48] M. Washington,et al. TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia , 2004, Science.
[49] K. Flaherty. Sorafenib: delivering a targeted drug to the right targets , 2007, Expert review of anticancer therapy.
[50] Brian Bierie,et al. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. , 2008, Cancer research.
[51] M. Teixeira,et al. The chemokine receptors CXCR1/CXCR2 modulate antigen-induced arthritis by regulating adhesion of neutrophils to the synovial microvasculature. , 2008, Arthritis and rheumatism.
[52] John D Nagy,et al. The ecology and evolutionary biology of cancer: a review of mathematical models of necrosis and tumor cell diversity. , 2005, Mathematical biosciences and engineering : MBE.
[53] D. McNeel,et al. Endothelin Receptor Antagonists in Cancer Therapy , 2007, Cancer investigation.
[54] Lisa M. Coussens,et al. Immune cells as mediators of solid tumor metastasis , 2008, Cancer and Metastasis Reviews.
[55] Kyle Summers,et al. Positive selection in the evolution of cancer , 2006, Biological reviews of the Cambridge Philosophical Society.
[56] A. Jemal,et al. Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.
[57] T. Tlsty,et al. Stromal cells can contribute oncogenic signals. , 2001, Seminars in cancer biology.
[58] Brian Bierie,et al. A delicate balance: TGF‐β and the tumor microenvironment , 2007, Journal of cellular biochemistry.
[59] Mel Greaves,et al. Cancer causation: the Darwinian downside of past success? , 2002, The Lancet. Oncology.
[60] Brian Bierie,et al. Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer , 2006, Nature Reviews Cancer.
[61] B. O'connor,et al. Heparin and structurally related polymers attenuate eotaxin‐1 (CCL11) release from human airway smooth muscle , 2008, British journal of pharmacology.
[62] Matthew J. Craig,et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. , 2007, Cancer research.
[63] W. Sierralta,et al. Marrow-derived mesenchymal stem cells: Role in epithelial tumor cell determination , 2004, Clinical & Experimental Metastasis.
[64] G. Jayson,et al. A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis , 2006, Expert opinion on therapeutic targets.
[65] P. Hein,et al. Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium , 2000, Breast Cancer Research.
[66] H. Moses,et al. Stromal fibroblasts in cancer initiation and progression , 2004, Nature.
[67] Robert J. Gillies,et al. A microenvironmental model of carcinogenesis , 2008, Nature Reviews Cancer.
[68] L. Coussens,et al. Polarized immune responses differentially regulate cancer development , 2008, Immunological reviews.
[69] C. Maley,et al. Cancer is a disease of clonal evolution within the body1–3. This has profound clinical implications for neoplastic progression, cancer prevention and cancer therapy. Although the idea of cancer as an evolutionary problem , 2006 .
[70] J. Elser,et al. Biological Stoichiometry in Human Cancer , 2007, PloS one.
[71] Thomas S. Deisboeck,et al. Modeling Tumors as Complex Biosystems: An Agent-Based Approach , 2006 .
[72] John Cairns,et al. Mutation selection and the natural history of cancer , 1975, Nature.
[73] K. Pienta,et al. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] V. Quaranta,et al. Integrative mathematical oncology , 2008, Nature Reviews Cancer.
[75] Z. Shao,et al. The human myoepithelial cell is a natural tumor suppressor. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[76] K. Pienta,et al. Evolution of cooperation among tumor cells , 2006, Proceedings of the National Academy of Sciences.
[77] Zeljko Vujaskovic,et al. Re-setting the biologic rationale for thermal therapy , 2005, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[78] T. Ratliff. TGF-Beta Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia , 2004 .
[79] K. Pienta,et al. Cancer as a complex adaptive system. , 1996, Medical hypotheses.
[80] Bert Vogelstein,et al. Genetic instability and darwinian selection in tumours , 1999 .
[81] P. Vineis. Cancer as an evolutionary process at the cell level: an epidemiological perspective. , 2003, Carcinogenesis.
[82] M. Begon,et al. Ecology: Individuals, Populations and Communities , 1986 .
[83] Noam Brown,et al. Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors , 2001, Journal of leukocyte biology.
[84] H C Charles,et al. Radiation therapy and hyperthermia improve the oxygenation of human soft tissue sarcomas. , 1996, Cancer research.
[85] F. Lee,et al. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor , 2008, Cancer Chemotherapy and Pharmacology.
[86] Stephen E. Jones. Metastatic breast cancer: the treatment challenge. , 2008, Clinical breast cancer.
[87] A. Veves,et al. DPP4 Inhibitors: a new approach in diabetes treatment , 2008, Advances in therapy.
[88] A. Moustakas,et al. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. , 2007, Biochimica et biophysica acta.
[89] J. Shaw,et al. Primary breast myoepithelial cells exert an invasion‐suppressor effect on breast cancer cells via paracrine down‐regulation of MMP expression in fibroblasts and tumour cells , 2003, The Journal of pathology.
[90] H. Moses,et al. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. , 2007, The Journal of clinical investigation.
[91] G. Roodman,et al. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. , 2007, Cancer research.
[92] A. Zwinderman,et al. A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue , 2008, Annals of the rheumatic diseases.
[93] G. Mundy. Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.
[94] T. Guise,et al. The vicious cycle of bone metastases. , 2002, Journal of musculoskeletal & neuronal interactions.
[95] Mel Greaves,et al. Darwinian medicine: a case for cancer , 2007, Nature Reviews Cancer.
[96] J. Klein-Nulend,et al. Prostaglandins differentially affect osteogenic differentiation of human adipose tissue-derived mesenchymal stem cells. , 2007, Tissue engineering.
[97] J. van der Zee,et al. First results of triple‐modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with Stage IIB, III, and IVA cervical carcinoma , 2005, Cancer.